Parkinson disease is a progressive neurologic disorder. Limited evidence suggests endurance exercise modifies disease severity, particularly high-intensity exercise.
P arkinson disease is a progressive neurodegenerative disorder characterized by rigidity, tremor, bradykinesia, and postural instability, ultimately leading to disability. 1, 2 Because medications have adverse effects and reduced effectiveness over time, 3 disease-modifying nonpharmacologic interventions are needed. One intervention, endurance exercise, promotes neurogenesis and neuroprotection in animals [4] [5] [6] [7] [8] and has had symptom-modifying and health-related benefits in patients with Parkinson disease. [9] [10] [11] [12] [13] Retrospective studies 14, 15 have found that moderate to vigorous exercise in midlife can protect against Parkinson disease. Studies 9, 16 in humans suggest that high-intensity endurance exercise improves motor symptoms, but current evidence is insufficient to determine whether exercise intensity influences symptom modification or disease progression. To date, no study has been conducted at 80% to 85% maximum heart rate, and typically most studies were powered on fitness or functional measures but not disease severity. [9] [10] [11] 17, 18 This study (Study in Parkinson Disease of Exercise [SPARX]) was a phase 2 randomized clinical trial to investigate the dose response of treadmill exercise performed at 2 different intensities (high and moderate). To remove the potential confounder of medication, this study included patients with de novo Parkinson disease. 19 The study examined whether patients with de novo Parkinson disease can consistently and safely exercise on a treadmill at high intensity (80%-85% maximum heart rate) or moderate intensity (60%-65% maximum heart rate) at least 3 days per week and whether high-or moderate-intensity treadmill exercise warrants further investigation for treatment of motor symptoms.
Methods

Study Design
SPARX was a randomized clinical trial in de novo Parkinson disease comparing high-and moderate-intensity treadmill exercise with usual care (a wait-list control group). 19 The setting was outpatient clinics and community-based exercise facilities. The institutional review board of each site approved the protocol (Colorado Multiple Institution Review Board; University of Illinois Institutional Review Board; Northwestern University Institutional Review Board Office; Institutional Review Board, Human Research Protection Office, University of Pittsburgh; and Rush University Medical Center Institutional Review Board). All participants provided written informed consent, and all data were deidentified. The trial protocol can be found in the Supplement.
Study Participants
Participants with idiopathic Parkinson disease 20 were enrolled from May 1, 2012, through November 30, 2015 , in Chicago, Illinois; Denver, Colorado; and Pittsburgh, Pennsylvania. Participants were aged 40 to 80 years, had Hoehn and Yahr stage 1 or 2 disease, 21 were within 5 years of diagnosis, were not exercising at moderate intensity more than 3 times per week, and were not expected to need dopaminergic medication within 6 months. Race/ethnicity was by self-report according to the National Institute of Neurological Disease and Stroke Common Data Elements. 22 
Screening, Baseline Testing, and Randomization
Prescreening occurred by telephone and in neurology clinics. Participants who met the criteria underwent baseline assessments, including a graded exercise test with measured maximum heart rate. Participants were randomly assigned to highintensity treadmill exercise (80%-85% maximum heart rate), moderate-intensity treadmill exercise (60%-65% maximum heart rate), or usual care. The usual care group was instructed to maintain exercise habits. Originally, permuted block randomization stratified by site was used for study assignment. The randomization lists were generated by the statistician (C.G.M.) and uploaded into a web-based data system. Assignment was concealed until a screened participant was deemed to be eligible. At approximately one-third of recruitment, a significant imbalance was detected among the 3 groups on the primary clinical outcome. With approval from the Safety Monitoring Committee, the randomization was changed to a minimal sufficient balancing strategy. 23, 24 Exercise Interventions Treadmill exercise was prescribed for 4 days per week for 26 weeks with an a priori hypothesized adherence of 3 days per week. Included were 5 to 10 minutes of warm-up, 30 minutes of treadmill exercise at the target heart rate, and 5 to 10 minutes of cool down. Exercise frequency and intensity were increased during weeks 1 to 8 to reach target levels. Thereafter, target heart rate was maintained by adjusting treadmill speed and/or incline. Rating of perceived exertion was used to monitor exercise intensity for participants who initiated use of chronotropic medications during the intervention.
Participants used a heart rate monitor to record intensity of all exercise sessions. All sessions in weeks 1 to 2 were supervised at the study site. Thereafter, participants exercised at the study site at least monthly, when heart rate data were downloaded. Protocol fidelity was ensured by monthly conference calls with study coordinators. 9 to 26, expressed as a percentage of the measured maximum heart rate. Adherence was determined by exercise frequency. The primary clinical outcome was the 6-month change in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score, 25 assessed by study neurologists (B.M.K., B.D.B., C.L.C., D.A.H., S.J.). If a participant began taking medication, the UPDRS was administered before initiation when possible. When participants changed medication without informing the study coordinators, the UPDRS from the last study visit without medications was used. In addition, any participant who had begun taking medication was asked to refrain from taking medication overnight for 12 hours and was tested while not taking medication. 26 Secondary outcomes included changes in UPDRS total and subscores and the Movement Disorders Society UPDRS (MDS-UPDRS) subscores, 27 as well as maximal aerobic power (Vo 2 max). 28 Daily step counts
were assessed by accelerometry. 29 Safety outcomes were monitored during exercise and monthly contact. 30 We used the UPDRS for our primary outcome measure because when we designed the study (2009), data were limited on the MDS-UPDRS as an outcome measure. We present the MDS-UPDRS data because this measure is currently recommended.
22,27,31
Statistical Analysis
Within-group achievement of the exercise intensity and frequency (hypothesized to be at least 3 days per week) was tested using 1-sample t tests. A log-rank test was used to compare the rates of Parkinson disease medication initiation. An intentionto-treat approach was used to compare 6-month UPDRS motor change in usual care to each exercise group with a priori, planned unpaired 2-sample t tests with 1-sided α = .10 and a futility threshold of θ = 3.5. 19 The null hypothesis being tested for each exercise arm independently was that the exercise intensity resulted in at least 3.5 points less change on the UPDRS motor score at 6 months compared with usual care and, thus, warranted further investigation. We estimated the between-group difference and compared the 90% upper confidence boundary with the 3.5-point futility threshold. Sensitivity analyses explored the effect of using off-state UPDRS scores for participants who initiated treatment and multiple imputation for missing data. Secondary outcomes were reported as differences in means with 95% CIs. The number needed per group for good precision (±2.5%) for mean intensity was 36 (95% CI half width of 2.4%, σ = 7.0%), providing 83% power to detect 3.5% intensity difference (σ = 7, α = .05). 19 A sample size of 36 finishers per group provided more than 84% power to reject the null hypothesis if there was no difference in the UPDRS motor score between the exercise and usual care groups (SDs, 5.5-6.5; 1-sided α = .10). We aimed for 42 participants per group, assuming 15% attrition at 6 months.
Results
Baseline Characteristics of Participants
We evaluated and screened 154 volunteers for eligibility; 128 were randomized (mean [SD] age, 64 [9] years; age range, 40-80 years; 73 [57.0%] male; and 108 [84.4%] non-Hispanic white) ( Figure 1 ). Groups were well matched across baseline characteristics ( Table 1) .
Feasibility Outcomes
Both exercise groups met targeted treadmill exercise intensity ( Figure 2A ). The mean percent maximum heart rates were 80.2% (95% CI, 78.8%-81.7%) for the high-intensity group and 65.9% (95% CI, 64.2%-67.7%) for the moderate-intensity group, with no changes over time (P = .25). Mean weekly treadmill exercise frequency was 2.8 (95% CI, 2.4-3.2) days per week for the high-intensity group and 3.2 (95% CI, 2.8-3.6) days per week for the low-intensity group (P = .13) ( Figure 2B ), with a slight negative trend over time (−0.02 per week, P < .001).
A similar proportion of participants in each group (5 [12%] high intensity, 10 [22%] moderate intensity, and 6 [15%] usual care) initiated use of medication before 6 months (log-rank test P = .40). Overall attrition was 8.6%. 
Futility Analysis Outcome
The mean change in UPDRS motor score in the high-intensity group was 0.3 (95% CI, −1.7 to 2.3) compared with 3.2 (95% CI, 1.4-5.1) in the usual care group ( Figure 2C) ; thus, high-intensity treadmill exercise led to less motor change compared with usual care and the null hypothesis was not rejected (P =.34)( Table 2) , indicating nonfutility and that high-intensity treadmill exercise warrants further investigation. Mean change in UPDRS motor score in the moderate-intensity treadmill exercise group was 2.0 (95% CI, 0.38-3.7) ( Figure 2C) ; thus, the null hypothesis that moderate-intensity exercise was associated with less change of motor symptoms compared with usual care was rejected (P = .03) ( Table 2) , indicating futility of further investigating moderateintensity exercise. Neither result (high-intensity nor moderateintensity treadmill exercise) was affected by imputation using off-state UPDRS assessments and multiple imputation for missing data (Table 2) .
Secondary Outcomes
The high-intensity treadmill exercise group had no difference in outcomes compared with usual care at 6 months for other UPDRS and MDS-UPDRS total scores and subscores, with the exception of MDS-UPDRS motor subscore, for which the high-intensity group had significantly less change (4.0; 95% CI, 0.4-7.5; P = .03) ( Table 2 ). The moderate-intensity treadmill exercise group had no differences compared with usual care at 6 months for all UPDRS and MDS-UPDRS measures. V o 2 max improved for participants in the high-intensity group and decreased in the usual care group during 6 months ( Table 2) . Change in total step count revealed no difference between groups (Table 2) .
Adverse Events
Adverse events related to endurance exercise were as expected ( Table 3) . Only 2 serious adverse events occurred, both in the moderate-intensity group and unrelated to exercise (Table 3) .
Discussion
Participants with Parkinson disease adhered to the prescribed exercise intensity and met the hypothesized test was used for categorical variables and 1-way analysis of variance for continuous variables. There were no significant between-group differences in any baseline characteristics. High-intensity treadmill exercise was 4 days per week at 80%-85% maximum heart rate; moderate-intensity treadmill exercise, 4 days per week at 60%-65% maximum heart rate.
b Calculated as weight in kilograms divided by the height in meters squared. e Activity was measured by waist-worn ActiGraph GT3X+ and GT3X-BT accelerometers (Actigraph); because of missing data, sample sizes are 36 for 80% to 85% maximum heart rate, n = 42 for 60% to 65% maximum heart rate, and 36 for usual care.
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High-Intensity Treadmill Exercise in Parkinson Disease frequency of 3 days per week during 6 months. The futility analysis indicated that high-intensity treadmill exercise warrants further investigation as an intervention for motor symptoms in de novo Parkinson disease. Adverse musculoskeletal events were expected with endurance exercise, based on previous exercise trials, 9, 10 and not serious, demonstrating that patients with Parkinson disease can exercise safely without direct supervision when guided by exercise specialists. The protocol was well tolerated as evidenced by the low attrition rate of 8.6%. In a previous study, 9 individuals with early-or middlestage Parkinson disease had an improved UPDRS motor score after 6 months of exercise at 69.7% (95% CI, 67.1%-71.8%) of age-predicted maximum heart rate. However, to our knowledge, no previous endurance exercise studies have found differences among different intensities. To date, no studies have been conducted in patients with de novo Parkinson disease to eliminate the confounding of medication, have been powered on the UPDRS motor score, or have used 80% to 85% of maximum heart rate measured throughout each session. We found that high-intensity treadmill exercise is feasible and attenuates worsening on the UPDRS motor score consistent with the clinically meaningful threshold of 3.5. 32 Furthermore, the between-group difference for the MDS-UPDRS motor subscores was comparable to the reported within-person minimal clinically important improvement of 3.2. 33 In light of a recent report that low-dose, patient-centered, goal-directed physiotherapy and occupational therapy in patients in the early stages of Parkinson disease is not effective, 34 a demonstration of the nonfutility of high-intensity treadmill exercise in patients with mild Parkinson disease is particularly important. This trial was designed to test whether each intervention was nonfutile compared with change in the control group regardless of the direction. The CI for the observed UPDRS motor score difference between the high-intensity and usual care groups included the a priori prespecified 3.5 points for nonfutility. Lack of UPDRS motor score improvement in the high-intensity group is not surprising, given that participants were de novo with a baseline mean UPDRS score of 17. With regard to exercise session frequency, we set 3 days as the adherence criterion in the protocol for feasibility and clinical relevance. We prescribed 4 days per week, recognizing that participants might miss some sessions.
The exercise dose met the guidelines for cardiovascular benefits of endurance exercise 35 and the recommendations of 150 minutes per week of moderate-intensity physical activity. 36 The high-intensity treadmill exercise group had an increase in V o 2 max of 1.9 mL/min/kg (8%) compared with baseline, whereas the usual care group had a decrease of 1.3 mL/min/kg (5%). This finding agrees with the 7% to 8% change in V o 2 max in patients with Parkinson disease reported by Shulman et al 11 for treadmill exercise at 70% to 80% heart rate reserve for 30 minutes.
No between-group differences were found in total daily step count change scores during 6 months. This finding suggests that exercisers reduced their daily steps outside their Six-month change in UPDRS motor score C 80%-85% Maximum Heart Rate 60%-65% Maximum Heart Rate Usual Care A, Percentage maximum heart rate for each intervention group at 60% to 65% maximum heart rate and 80% to 85% across weeks 9 to 26. B, Mean days exercised for each intervention group across weeks 9 to 26. In A and B, symbols represent the means and bars are the SEs. Trends over time were tested using linear mixed models. C, Distribution of the 6-month Unified Parkinson's Disease Rating Scale (UPDRS) motor change scores (6 months minus baseline), in which a positive change indicates worsening of motor symptoms. Each boxplot contains the median (horizontal line in the box), the upper quartile (75th percentile, top of box), the lower quartile (25th percentile, bottom of box), the mean (diamonds), whiskers, and outliers that are beyond 1.5 times the interquartile range (75th percentile minus the 25th percentile) from the 25th or 75th percentiles (circles). For usual care, the whiskers extend to the observed minimum and maximum. For the 80% to 85% maximum heart rate and the 60% to 65% maximum heart rate, the whiskers extend to the maximum and minimum values observed that were not outliers.
High-Intensity Treadmill Exercise in Parkinson Disease
Original treadmill-training period such that overall step counts remained similar throughout the day. We did not provide patients with advice for what to do in the nonexercise period of the day. van Nimwegen et al 37 reported that exercise training coupled with behavioral modification training increased total physical activity and daily energy expenditure in patients with Parkinson disease. Because sedentary behavior is an independent risk factor for all-cause mortality, 38 understanding how structured exercise affects nonexercise physical activity behaviors in patients with Parkinson disease will provide important clinical information on how to maximize the long-term therapeutic benefits of exercise in this population. This phase 2, multicenter futility design is of particular importance for the study of exercise in patients with Parkinson disease for several reasons. Only a few moderately sized exercise studies 10, 11, 39, 40 have been reported in this population.
One of the limiting factors to moving to phase 3 trials is that the appropriate dose of exercise has yet to be established for any exercise modality. Exercise imposes a substantial participant commitment of time and effort compared with pharmacologic interventions. The futility design was used to specifically establish whether further study of specific exercise dose is warranted, proving a method to efficiently determine the appropriate dose before moving forward to the first phase 3 exercise trial in Parkinson disease. Findings of nonfutility of high-intensity treadmill exercise should move the field forward substantially.
Limitations
Our study has limitations. It was highly controlled, with only treadmill training allowed; thus, other modes of endurance exercise 16, 41 were not evaluated but should be in future investigations. We manipulated both treadmill speed and incline; it is not clear whether one or both can affect motor symptoms of Parkinson disease. It has been argued that cadence is the key variable to improve motor symptoms in Parkinson disease. 16 To minimize participant burden, a High-intensity treadmill exercise was 4 days per week at 80%-85% maximum heart rate; moderate-intensity treadmill exercise, 4 days per week at 60%-65% maximum heart rate.
b Difference between the usual care group changes and the exercise group changes. The CIs are 1-sided 90% CIs for the primary outcomes and 2-sided 95% CIs for the secondary outcomes. For the primary outcomes, a 90% upper confidence bound for Δ that is greater than 3.5 indicates that the data are consistent with the hypothesis that exercise is associated with a 3.5 lessening of motor symptom progression on the UPDRS motor score. c The t statistic represents the comparison of each exercise group's mean change with the mean change in the usual care group relative to the variability of these changes and sample sizes in the groups. For the primary outcomes, t values and P values are null adjusted for the 3.5 futility threshold and 1-sided test (α = .10). A t value less than −1.28 (P < .10) indicates that data are not consistent with the hypothesis that exercise is associated with a 3.5 lessening of motor symptom progression on the UPDRS motor score. For the secondary outcomes, t values and P values are 2-sided tests with null equal to 0 (α = .05). g Activity was measured by waist-worn ActiGraph GT3X+ and GT3X-BT accelerometers (Actigraph). 
Research Original Investigation
Conclusions
We demonstrated feasibility and safety of high-intensity treadmill exercise in patients with de novo Parkinson disease. A larger efficacy trial is warranted to determine whether exercising at 80% to 85% maximum heart rate produces meaningful clinical benefits in de novo Parkinson disease. Meanwhile, clinicians may safely prescribe exercise at this intensity level for this population. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. High-intensity treadmill exercise was 4 days per week at 80%-85% maximum heart rate; moderate-intensity treadmill exercise, 4 days per week at 60%-65% maximum heart rate.
b Includes fall events. 
High-Intensity Treadmill Exercise in Parkinson Disease
Study Objectives
The overall objective of this Phase II study is to determine the futility or non-futility of conducting a Phase III randomized controlled trial to determine the effects of exercise on the progression of PD symptoms. The primary aim is to determine whether individuals with de novo Parkinson's disease (naïve to drug treatment) can achieve the randomly assigned levels of mean exercise intensity (60-65% HRmax or 80-85% HRmax) and adhere to the exercise protocol. The secondary aims are to determine: 1) whether moderate-or high-intensity endurance exercise [or both] warrants further investigation as a therapeutic intervention for motor symptoms in the treatment of de novo Parkinson's disease by conducting a futility trial, and 2) the incidence of adverse events and 6-month attrition associated with endurance exercise for each exercise arm (i.e., mean 60-65% HRmax and mean 80-85% HRmax groups).
Design and Outcomes
This will be a Phase II, multisite, randomized, evaluator-blinded, no exercise controlled, and exploratory clinical trial of the effects of 26 weeks of endurance exercise on the ability of patients with Parkinson's disease to exercise at the assigned heart rates. Outcome variables include:
Exercise intensity Change in UPDRS motor Adherence to exercise Attrition Adverse events Interventions and Duration One hundred twenty-six patients will be randomly assigned to 3 groups: 1) 80-85% HRmax; 2) 60-65% HRmax; 3) no-exercise control (42 patients per group). The entire intervention period is 12 months, with the primary end point at 6 months. After 6 months, the control group 1, 2 will be randomized to exercise for 6 months and the intervention groups will continue to exercise at their prescribed dose for 6 additional months. The endurance exercise will be 4 days per week for approximately 50 minutes per session (including warm up and cool down). Evaluations will take place using the following schedule:
Baseline, 6 and 12 months: Unified Parkinson's Disease Rating Scale (UPDRS and MDS UPDRS), HR average during exercise, days per week of exercise, attrition, quality of life (PDQ-39 and RAND), sleep (Epworth and PDSS-2) fatigue (Modified Fatigue Impact Scale), and health status (HSU) will be assessed. If participants have initiated dopaminergic therapy prior to the 6 or 12 month assessments, subsequent UPDRS evaluations will be conducted in the off-medicated state after overnight (12 hour) withdrawal from medication. (These data will be used for secondary analysis). Self-reported depression (BECK) and cognitive function (MoCA) will be assessed at screening visits, 6 and 12 months, but not at baseline. Each Month: Physical activity level and general health status (including initiation of dopaminergic therapies) will be documented. Should subjects require dopaminergic therapy within the first 6 months of the study, they will be tested immediately prior to initiating the drug therapy (evaluations should be the same as the month 3 assessment involving UPDRS and MDS UPDRS only).
Month 3: UPDRS and MDS UPDRS If a participant initiates dopaminergic therapy prior to the 3 month assessment, subsequent UPDRS evaluations will be conducted in the off-medicated state after overnight (12 hour) withdrawal from medication. (These data will be used for secondary analysis) Approved: 08/ 28/ 2014
Continuously: Falls, adverse events (AEs), and Serious Adverse Events (SAEs) Sample Size and Population Our target population is 126 persons diagnosed with de novo Parkinson's disease. Randomization will be stratified by site.
STUDY OBJECTIVES
Primary Objective
The Primary Aim (PA1), on which this exploratory Phase II clinical trial is powered, and the primary Hypothesis (H1) is: i. PA1: To test whether individuals with de novo Parkinson's disease (naïve to dopmainergic drug treatment) can achieve the randomly assigned levels of mean exercise intensity (60-65% average HRmax or 80-85% averge HRmax) and adhere to the exercise protocol. ii. H1: Patients assigned to the 80-85% HRmax group will exercise at a 20% higher relative intensity than those in the 60-65% HRmax group and both groups will demonstrate adherence levels of ateast 3 days per week.
Secondary Objectives
Secondary Aims (SA) are: i. SA2: To determine if intense endurance exercise warrants further investigation as a therapeutic intervention for motor symptoms in the treatment of de novo Parkinson's disease by conducting a futility trial. In an efficacy trial, the null hypothesis is that treatments are equivalent and rejection of the null hypothesis indicates one treatment is more effective than the other. In contrast, in a futility trial the null hypothesis is that the treatment has promise and will produce results exceeding a meaningful threshold . The alternate hypothesis in a futility trial is that treatment is not sufficiently different from control to warrant further investigation and is therefore futile. ii. H2: The exercise groups will demonstrate potential for therapeutic efficacy using a futility threshold of =3.5 points ( = UPDRS control-UPDRS exercise) on the UPDRS motor scale at 6 months or last visit prior to dopaminergic therapy being initiated within 6 months, when compared with wait-listed no exercise control group. iii. SA3:To estimate the incidence of adverse events and 6-month attrition associated with endurance exercise for each exercise arm (i.e., mean 60-65% HRmax and mean 80-85% HRmax groups). iv. H3: For each treatment arm, there will be a low incidence of exercise-related adverse events (10%) and 6-month attrition (<15%).
BACKGROUND
Rationale
i. Subjects will be individuals with primary PD who have not yet begun dopaminergic pharmacological interventions (de novo PD). ii. The intervention regimens consist of endurance exercise performed at either moderate (60-65% HRmax) or high (80-85% HRmax) intensity. The exercise will be delivered via treadmill training, 4x per week for 26 weeks. Subjects then will be encourged to continue to exercise for an additional 26 weeks at the prescribed training level. The control subjects will not exercise for the first 26 weeks but will be offered the exercise intervention for the second 26 weeks. Controls will be randomly assigned to one of the two exercise intensities. iii. The rationale for the two exercise intensities include: 1) the ranges are within the guidelines for safe endurance exercise for older adults; 2) they have been chosen to detect a minimum difference of 15% in average exercise HR between the groups and a mean difference of 20% (82.5% -62.5% = 20%); and 3) The highest intensity (80-85% HRmax) has been demonstrated to be feasible in our preliminary work. iv. Data from primate models of PD indicate HR demand may be important for symptomatic change and potential neuronal plasticity. 1 The frequency investigated in animal studies ranged from several times a week to every day to multiple times per day. [2] [3] [4] [5] Findings from our investigation will establish if there Approved: 08/ 28/ 2014 showed that individuals aged 60-71 benefitted from an exercise program in which the intensity averaged 80±5% HRmax with increases in VO2max of ~25%. This adaptation was independent of sex, age, and initial level of fitness. The proposed high-intensity exercise intervention is modeled after this study. In 2008 Fisher and colleagues 5 compared high-intensity activity (75% age-appropriate maximal heart rate but with a range from 50% to 75%) with low-intensity (50% or less) on several measures including the UPDRS and altered cortical excitability in patients with Parkinson's disease. They found small changes in the UPDRS total score but performed no statistical analyses. They did show that the cortical silent period was lengthened in the high-intensity group. Because the late part of the silent period duration is thought to reflect long-lasting cortical inhibitory processes, the idea is that high-intensity exercise may restore these inhibitory processes. In 2009, Ridgel and colleagues 7 compared forced exercise (high pedaling rate forced by a trainer on a tandem bike) with voluntary exercise in individuals with PD. Both groups exercised at 60-80% of HRmax. The forced group reduced their motor UPDRS score by 12 points (35%) whereas the other group did not. This study was an important 'proof of concept' study to demonstrate the potential PD-specific benefits of exercise, but the exercise mode is not clinically practical. Nevertheless, the clinical effect was striking and, if reproduced using treadmill training, would change clinical practice. In 2010 Mehrholz and colleagues 8 conducted a meta-analysis of exercise interventions in patients with PD and concluded that: "Patients with Parkinson's disease who receive treadmill training are more likely to improve their impaired gait hypokinesia. However, the results must be interpreted with caution because there were variations between the trials in patient characteristics, the duration and amount of training, and types of treatment. Additionally, it is not known how long these improvements may last." vi. In summary, the literature suggests that: 1) older adults respond well to intense exercise; 2) changes in cortical excitability in patients with PD suggest a generalized response to exercise that is consistent with the animal studies; and 3) changes in gait hypokinesia in response to exercise training are consistent with specificity of training principles. vii. Issues that remain to be determined include the extent to which endurance exercise can mitigate the symptoms of PD, the mechanism by which such benefits occur, and whether there is a dose-response effect of exercise. In 2011, Speelman and colleagues 9 concluded that: "In rodent models of Parkinson disease, which rely on administration of neurotoxins (6-OHDA or MPTP) to induce parkinsonian symptoms, exercise attenuates the degree of injury to midbrain dopaminergic neurons, and restores basal ganglia function through adaptive mechanisms of dopamine and glutamate neurotransmission." However, to the best of our knowledge the intensity of exercise has not been explicitly manipulated using relative heart rate or oxygen consumption levels. Furthermore, the physiological mechanism by which changes in PD symptoms are improved in response to exercise are not well understood, but one possibility is increased cortical vascularity. It will be impossible to determine the mechanism(s) by which exercise mitigates symptoms of PD in humans until the dose of exercise is established and beneficial effects of exercise are confirmed in a Phase III clinical trial. viii. To summarize the relevance of this proposed investigation, we quote from Speelman et al 9 who stated that "Accumulating evidence suggests that patients with PD might benefit from physical activity and exercise in a number of ways, from general improvements in health to disease-specific effects and, potentially, disease-modifying effects (suggested by animal data). Many issues remain to be addressed, including the need to perform clinical trials to demonstrate these presumed benefits of physical activity and exercise in patients with PD." Approved: 08/ 28/ 2014
Supporting Data
i. Exercise can both regulate brain function [10] [11] [12] [13] and modify the symptoms of PD.
14 There is mounting evidence that it also protects against neurological damage in animal models. Both symptom-and diseasemodifying effects of exercise are important to understand. In this exploratory trial, we are focusing on symptom-modifying effects because this is the necessary first step in understanding the dose-response effects of endurance exercise. Once the dose-response effects on PD symptoms are known, further studies can investigate protection against neurological damage. We are aware that the recent Physical Activity Guidelines Advisory Committee Report (http://www.health.gov/PAGuidelines/Report/membership.aspx) provided strong evidence for the multiple health benefits of moderate-intensity physical activity (i.e.,65% HR max). The Executive Summary of the Report further indicated that there is strong evidence that vigorous-intensity exercise (i.e.,80% HR max) is associated with greater improvements for some health outcomes compared to those observed with moderate-intensity exercise. Additionally, disease-modifying effects of exercise may require high-intensity exercise. The proposed protocol will investigate the potential benefits of moderate vs vigorous-intensity exercise on PD symptom modification. ii. The premise for the study was based on the growing evidence for neuronal plasticity following brain damage. 15 Several principles have emerged for modifying the symptoms of neurological insult including the following: specificity of training is important, repetition is critical, and exercise intensity matters. Investigators have applied these principles to animal models of PD with at tempts to reduce the parkinsonian symptoms resulting from neurochemical damage. 4, 16, 17 Two approaches have been used: emphasis on skill development 17 or on gait.
1, 4, 16
The mechanism by which exercise modifies brain function is not well understood but one possibility is increased cortical vascularity. 10 It will be impossible to determine the mechanism(s) by which exercise mitigates symptoms of PD in humans until the dose of exercise is established and beneficial effects of exercise are confirmed in a Phase III clinical trial. iii. We have chosen to use treadmill exercise to challenge gait for 3 reasons: 1) with respect to specificity, impaired gait is one of the critical symptoms associated with PD; 2) repetition is a required part of training; and 3) it is easy to control intensity of exercise. The necessary intensity cannot yet be inferred from the animal literature. Intensity is typically not measured using HR in rodent models, nor can it be discerned how HR demand in a rodent model relates to humans. With respect to endurance exercise in people with PD, a number of investigators have examined changes in PD symptoms and functional performance in response to increasing levels of exercise and, in some cases increasing intensity.
5, 18-23
To date, none of these studies were designed to provide definitive data. iv. The major risk from this exercise intervention is that subjects may develop muscle soreness or strains.
These adverse events are common with exercise for adults of any age. The occurrence of such events will be minimized by gradually increasing the exercise intensity and duration to the target levels during the first 8 weeks of training. In a study of 34 people in stages 1-3 of PD who participated in an endurance exercise program at 65-80% HRmax, there were 2 reports of sprains 11 reports of soreness in the first 4 months of supervised treadmill exercise. All of these events resolved without the need for the subject to leave the study. v. There is also a possibility that exercise will lead to an increase in falls. Although falls are common among people with PD 24, 25 , subjects with de novo PD are in the earliest stages of PD, before falls become problematic. Additionally, in a study of 34 people in later stages of PD (i.e., already on dopamine replacement therapies, Stages 1-3 of Hoehn and Yahr) who exercised for 16 months using a similar protocol, only 1 non-injurious fall occurred during treadmill exercise (Schenkman, unpublished results). vi. There is a potential risk of cardiac events during high-intensity exercise. The risk of death from an exercise test has been estimated to be 1 in 10,000. 26 The risk of a heart attack is about 4 in 10,000 and the risk of a problem that would require hospitalization (for example, chest pain) is about 2 in 10,000. 26 We will minimize the likelihood of this happening by having each patient carefully screened prior to entry into the study. See section 4.1.2.b. for further details.
STUDY DESIGN
i. This is a Phase II, multisite, randomized, evaluator-blinded, no-exercise controlled, exploratory clinical trial of the effects of 26 weeks of endurance exercise on the ability of patients to exercise at the assigned target heart rate ranges. Subjects in the exercise arms will be encouraged to continue to exercise for an additional 26 weeks (52 weeks total). Outcome variables include the following: Exercise intensity Change in UPDRS motor Adherence to exercise Attrition Adverse events ii. A futility analysis will determine whether changes in the UPDRS are sufficient with either or both of the exercise intensities to warrant a Phase III clinical trial. If so, the subsequent trial may include assessment of the mechanisms of such changes. iii. Figure 1 summarizes 
3-month UPDRS and MDS UPDRS
Selection and Enrollment of Subjects
Primary Inclusion/Exclusion Criteria
Inclusion Criteria
i. Primary PD diagnosed by a neurologist who is a movement disorders specialist, using UK Brain Bank Criteria ii. The UK Parkinson's disease Society Brain Bank clinical diagnostic criteria are a three-step process as listed below. We are listing all criterion but will not be using those related to levodopa.
Step 
Exclusion Criteria
i. Makuna ii. Use of any PD medication within 60 days prior to the baseline visit including levodopa, direct dopamine agonists, amantadine, Rasagiline (Azilect), Selegiline (Eldepryl), Artane (trihexyphenidyl). iii. Duration of previous use of medications for PD that exceeds 90 days. iv. Expected to require such treatments in the next 6 months. v. Regular use of neuroleptics/dopamine receptor blockers. Occasional previous neuroleptic use as an antiemetic is allowed if not within six months prior to baseline visit.
Poorly controlled or unstable cardiovascular disease. Resting blood pressure >150/90 mmHg. CBC: out of range and physician's judgment Beck depression score > 16, indicating depression that precludes ability to exercise. Any subject with such a score will be referred to a PCP or physician for further evaluation and management of depression. vi. Stable doses of psychotropic medications are allowed (e.g., anxiolytics, hypnotics, benzodiazepines, antidepressants) if the dose has been stable for 28 days prior to screening. Investigators will strive to avoid or minimize changes in such medications; however, if clinical situations require a dosage change, introduction, or discontinuation of psychotropic medications, these changes will be recorded, and the subject will be permitted to remain in the trial. Hypo-or hyperthyroidism (TSH <0.5 or >5.0 mU/L), abnormal liver function (AST or ALT more than 2 times the upper limit of normal), abnormal renal function (serum creatinine >2 mg/dL). vii. Montreal Cognitive Assessment (MoCA) score of <26/30 (mild cognitive impairment (MCI). 27 Disorders that interfere with ability to perform endurance exercises (e.g., stroke, respiratory problems, traumatic brain injury, or neuromuscular disease) Any clinically significant medical condition, psychiatric condition, drug or alcohol abuse, or laboratory abnormality that would, in the judgment of the physician, interfere with the ability to participate in the study. Regular participation in vigorous endurance exercise, defined as >2 days/week for at least the past 4 months at moderate to vigorous exercise (e.g., > 65% HR MAX). Evidence of serious arrhythmias or ischemic heart disease using a graded exercise test (GXT). The test will be administered by a health care professional trained to interpret blood pressure and ECG responses to exercise. Individuals with a positive treadmill test will require a follow-up diagnostic evaluation by a cardiologist to rule-out cardiovascular disease before they can be enrolled.
Secondary Inclusion / Exclusion Criteria
Disorder
Subjects will be included who have primary Parkinson disease as determined by a neurologist who is a movement disorders specialist using the UK PD brain bank criteria (e.g., bradykinesia and at least one of tremor, rigidity, or postural instability).
28-30
Primary PD refers to parkinsonism not due to secondary causes such as cerebrovascular event or supranuclear palsy. They will be in Hoehn and Yahr stage less than stage III, and disease duration less than 5 years and will not be likely to require dopaminergic therapies within 6 months.
Clinical Indicators of Current Status
Clinical indicators of current status will include screening tests to rule out cardiovascular or other disorders that preclude exercise at 80%-85% HRmax. Failed screening tests (e.g., high blood pressure) can be remediated. If the issue is resolved in time to reach randomization within 8 weeks from signing of the informed consent, the subject will continue through screening and baseline testing. If the remediation is outside of the 8 week window, the subject will be rescreened by the neurologist.
Screening Procedures
Subjects will be assessed for severity of Parkinson disease.
A blood draw will screen for medical conditions that could contradict exercise training or influence the adaptive response to exercise. A graded exercise test will be performed to screen for conditions that could contradict exercise training (e.g., serious arrhythmias, ischemic heart disease). The sample will be between ages 40 and 80. Parkinson's disease typically affects men to women at a ratio of 2:1. Therefore, we anticipate enrolling subjects in this ratio at all three sites.
Serious Illness Approved: 08/ 28/ 2014
Serious illness (requiring systemic treatment and/or hospitalization) will preclude enrollment until subject either completes therapy or, in the opinion of the site investigator, is clinically stable on therapy for at least 4 weeks prior to study entry. Should a subject have a serious illness during the screening period, s/he will be referred back to the neurologist to determine whether the screening can continue. Figure 2 , pp. 19-20 outlines all study procedures and time frames.
Study Enrollment Procedures
Subjects will be:
1) referred from the Movement Disorders Center at each site, 2) referred by community neurologists and movement disorders specialists, or 3) self-referred. The majority of subjects interested in participating in the study are expected to be current patients in the Movement Disorder clinics. Others will be referred by community neurologists or may self-refer in response to advertisements or posting on Clinicaltrials.gov. Origin of the referral will be documented. Subjects who do not meet the eligibility criteria will be recorded. Subjects who qualify for the study and decline participation will be asked to indicate their reasons for refusal to participate and these will be recorded. Each site will collect the same information in the screening log. Individual sites will monitor recruitment on a weekly basis. The Steering Committee will monitor study recruitment at least on a monthly basis and based on those data will determine whether alternate recruitment strategies should be instituted.
Screening Procedures
Subjects must provide written informed consent prior to implementation of any study procedures. This will take place in a quiet, private room. Once the subject has read over the document, a member of the investigative team will review the entire document to be sure that the procedures and time commitments are understood. Comprehension and autonomy will be assessed by asking subjects to explain in their own words what the study is about. The subject will sign the consent form, complete a Demographic questionnaire and Beck's depression Inventory, and then the member of the investigative team will administer the Montreal Cognitive Assessment (MoCA). The neurologist will complete a neurological examination, to confirm eligibility (e.g., primary PD) and a physical examination to evaluate eligibility for the study. A metabolic panel, complete blood count and TSH will be obtained to evaluate health status. Under the supervision of a clinician, a GXT to volitional exhaustion will be performed to assess blood pressure and ECG responses to exercise. VO 2 Max will be determined during the graded exercise test. The research assistant will enter all eligibility information into the electronic database. Once the data for these screening procedures are fully entered and the subject is deemed eligible, the site neurologist will sign off on the medical exclusions and the site PI will sign off on eligibility. The subject then will complete all baseline data collection. Control participants who wish to exercise will be rescreened for metabolic panel, complete blood count and TSH, the physical and neurologic exam and a GXT at the end of six months and within two weeks of beginning exercise.
Baseline Testing
UPDRS and MDS UPDRS will be administered by a neurologist who is a movement disorders specialist. Physical activity will be monitored for one week, using the ActiGraph GT3X+ activity monitor for data collection. (Subjects will receive the physical activity monitor at the beginning of data collection and will return the physical activity monitor one week later).
The following questionnaires will be completed: Modified Fatigue Impact Scale (MFIS) Once these data have been obtained, the research assistant will randomize the subject. The group assignment will be provided on the screen. Allocations for subsequent subjects will remain concealed.
Randomization
Subjects will be randomized to 1) no-exercise control (i.e., usual care); 2) exercise 4x per week at 60-65% HRmax; or 3) exercise 4x per week at 80-85% HRmax. The study biostatistician will generate the randomization sequences for each site in SAS version 9.2 using permuted block randomization with random block sizes. The University of Pittsburgh Center for Research on Health Care Data Center systems analyst will load the randomization list into the web-based data management system such that allocation concealment will be preserved for consecutively enrolled subjects. The regimen will include 5-10 min of warm up, 30 min of exercise at target HR and 5-10 min of cool down. They will exercise 4 days per week. The two intervention groups will be given a HR range to achieve during exercise sessions: 60-65% or 80-85% of HRmax. This will lead to a mean HR for the groups of 62.5 ± 2.5% and 82.5 ± 2.5% of HRmax respectively. In this way, the difference in mean HR between the groups should be 20% of HRmax while the minimum and maximum differences should be 15 and 25. During the first 8 weeks of training, exercise duration and intensity will be gradually increased to the target levels. Subjects will be instructed on monitoring HR and adjusting the exercise to remain in the target HR range (i.e., by changing treadmill speed and/or incline). During exercise, subjects will wear a heart rate monitor that captures and stores HR throughout the exercise bout. The exercise Research Assistant (RA) will electronically transfer the HR file from each exercise session (supervised and unsupervised) into the study database.
5.1.2.
During the first 2 weeks, subjects must exercise at a main study site under supervision of an Exercise training RA. All 'on-site' exercise sessions will be supervised by an exercise RA. After 2 weeks, the RA will determine whether the subjects may exercise off-site at a community fitness facility or at home to maximize the likelihood of compliance. If the subjects are exercising in their target HR range for the prescribed duration and have demonstrated to the exercise RA that they are able to operate the HR monitor, the subjects will exercise 2X/wk at the main site for 2 weeks and then 1X/wk for 2 weeks. Thereafter, if cleared by the RA, subjects will be expected to exercise on-site at least 2 x/month at the main site. Other exercise sessions will take place at the approved off-site facility. HR monitors must be worn for all sessions. HR data will be downloaded once weekly by an approved person at the facility or brought to a main site to be downloaded by the RA. In addition, the subject will be given an exercise diary log to document his/her were time sessions on a weekly basis. The RA will check adherence to their prescription each week and will work with the participant as needed to assure appropriate adherence to the protocol.
5.1.3.
The intent of allowing exercise off site is to enhance recruitment, retention, and long-term adherence to exercise. Cardiovascular safety is assured by the screening GXT. Safety with respect to treadmill exercise will be established for each subject during the first two weeks of exercise at the main study site and also has been established in our previous work for by 34 subjects with PD, Stages 1.5-3 of H&Y who exercised for up to 16 months without incident (Schenkman, unpublished data). Additionally, many of the designated health clubs we work with are affiliated with hospitals and specialize in exercise programs for people with PD.
5.1.4.
The exercise training RA will assure exercise fidelity for each subject by comparing exercise sessions, duration and mean HR to the subject's target on a weekly basis and by working with the subject to make necessary adjustments.
5.1.5.
At the completion of the 6-month exercise intervention, subjects will be encouraged to continue to exercise, using the same protocol as for the first 6-months. Adherence will be assessed after the first six months (primary end point) and again after an additional 6 months (12 months).
5.1.6.
Control group: Subjects will be asked not to change their usual exercise habits for 6 months. On completion of the control period, subjects will be randomly assigned to 60-65% HRmax or 80-85% HRmax for six months of follow up.
5.1.7.
At the completion of 6 and 12 months from enrollment in the study, all outcome data (VO 2 MAX, UPDRS and MDS UPDRS, and questionnaires) will be repeated for all subjects.
Handling of Study Interventions
5.2.1.
Each subject will, of necessity, be aware of group assignment. However, study personnel who collect the following outcome measures (i.e., UPDRS, exercise intensity [HR and duration]) will be blinded to the subject's group assignment as will the site P.I., Co-Is, including the statistician. The site P.I., Co-Is, including the statistician will be blinded to other outcome measures (e.g., HR at which subjects exercise; adherence). These data are collected electronically by the treating RA, and are used by the RA to assist subjects to adhere to their prescribed exercise regimen. Approved: 08/ 28/ 2014
Concomitant Interventions
5.3.1. Subjects are precluded from enrolling in other studies or interventions that could affect their UPDRS motor score or VO 2 MAX (e.g., drug trials, exercise studies.)
Adherence Assessment
5.4.1.
Compliance will be assessed by documenting number of days of exercise as well as actual exercise duration and HR intensity for each exercise session. Subjects will wear a Polar Heart Rate Monitor during each exercise session. These monitors store HR during the session as well as the time exercised.
CLINICAL AND LABORATORY EVALUATIONS
Schedule of Evaluations
Before Study This trial follows an intention-to-treat design. Subjects who discontinue intervention will be followed and evaluated as if they were still taking part in the exercise protocol. The study coordinator will contact the subjects who elect to discontinue on a monthly basis and will make every effort to retain such subjects in the study. When practical, the subjects will be encouraged to resume the study intervention. They will be encouraged to resume at their specified level but, if exercise intensity is an issue, will be encouraged to take part at whatever level they can. Subjects in the control group who start to exercise during the control period will be encouraged to maintain their previous activity level during the control period.
On Study/Off-Intervention Evaluations
Since this study is intention to treat, all evaluations will continue even if the subject is no longer following the treatment regimen.
Final On-Study Evaluations
Final On-Study evaluation will take place within three weeks of the 12 month end point. The evaluation will include the following: Confirmation of primary PD Repeat of the UPDRS, MDS UPDRS and VO 2 MAX Questionnaires Activity Monitors
Off-Study Requirements
Primary and secondary outcomes will be ending at 6 months. Subjects in the two intervention arms will be encouraged to continue on the exercise protocol until 12 months. The final study visit will be at the end of 12 months from initial exercise. The control group can exercise past the assessment, but the UPDRS must be done at 26 and 52 weeks. Wait listed controls will begin to exercise after the 6 month outcomes assessment and will continue on their exercise protocol until 12 months. Their final study visit will be at 6 months following the beginning of their exercise.
Special Instructions and Definitions of Evaluations
Informed Consent
Informed consent will be obtained at the initial screening visit before the neurological examination and UPDRS are completed. A model informed consent is in the Appendix.
Medical History
A check list will be used during the medical examination to make sure that all conditions for which subjects might be excluded are assessed. Treatment History: Medical status and pharmacological interventions will be monitored on a monthly basis throughout the study.
Concomitant Treatments
We will document all concomitant treatments and the condition for which the subjects are being treated. These will be documented monthly using the Health Status Update questionnaire.
Study Intervention Modifications
The goal of this study is to determine futility / non-futility of high and moderate aerobic endurance exercise. There is sufficient evidence for the safety of endurance exercise at the planned intensities, both for people with and without specific disorders, hence there are no stopping rules. Should subjects experience adverse events (e.g., muscle soreness that inhibits or prevents exercise in a normal manner) during the exercise phase; the program will be modified as necessary and then gradually increased back to the prescribed training level.
Clinical Assessments
A maximal graded exercise test (GXT) will be performed under the supervision of a clinician during screening to determine whether exercise generates serious arrhythmias or changes in the ECG consistent with ischemia and to measure HRmax. A resting 12-lead ECG will be recorded in the recumbent and upright positions immediately prior to the exercise test. If the findings on the resting ECG do not contraindicate exercise, the exercise test will be performed. Approved: 08/ 28/ 2014
Contraindicators include the following: (a) ST-segment depression of more than 0.2 mV that is either horizontal, downsloping, or slowly upsloping (less than 1 mV/sec) and lasts for 0.08 sec, or ST-segment elevation greater than 0.1 mV; (b) chest pain or discomfort; (c) serious arrhythmias, including multifocal PVCs, ventricular tachycardia, frequent (>10/min) PVCs or couplets, or sustained atrial tachyarrhythmias; (d) A-V block or other conduction defects; (e) a fall of systolic blood pressure of 10 mmHg or greater from the peak level with increasing exercise intensity; (f) diastolic blood pressure above 110 mmHg or systolic above 220 mmHg; (g) dizziness; (h) ataxic gait; and (i) pallor or cyanosis. False positive GXTs are not uncommon in middle-aged and older adults. Subjects who have a positive GXT will be required to pursue a follow-up diagnostic evaluation and clearance by a cardiologist if they want to continue to be considered for enrollment in the study. Maximal aerobic power (VO 2 max) will be measured by indirect calorimetry (TruMax 2400, ParvoMedics, Sandy, UT) during the GXT. A warm-up period on the treadmill will be used to identify the walking speed that generates a HR that is 65-70% of the age-predicted HRmax; for fit individuals, this may require increasing the elevation of the treadmill. After a brief rest interval to initiate the indirect calorimetry, the test will start at the designated walking speed (and grade).
The treadmill grade will be increased by 2% every 2 minutes to volitional exhaustion or until the proctor stops the test because of abnormal responses to exercise. Unified Parkinson's Disease Rating Scale (UPDRS) and Movement Disorder Society -Unified Parkinson's Disease Rating Scale (MDS-UPDRS will be used to assess severity of symptoms of Parkinson's disease, daily activities, motor skills and mental capacity. These scales will be administered at baseline, 3 months, 6 and 12 months.
Additional Evaluations
Activity Monitors. These will be used to assess physical activity level monthly.
Questionnaires
PDQ-39 and RAND will be used to assess quality of life at baseline and at each follow up time (6 and 12 months). A Health Status Update questionnaire will be used monthly to assess changes in health condition, including medication changes. PDSS-2 and Epworth sleep scales will be administered to assess sleep at baseline and at each follow up time (6 and 12 month). MFIS will be used to assess fatigue at baseline and at each follow up time (6 and 12 month). BECK depression scale will be used to screen and assess changes in self-reported depression a screening and at each follow up time (6 and 12 month). Montreal Cognitive assessment (MoCA) will be used to assess changes in cognitive function at screening and at each follow up time (6 (v. 2) and 12 (v. 3) month). PD Therapy Warranted Survey will be completed by the neurologist should complete at 3, 6 and 12 months and also at any UPDRS/MDS UPDRS related visit just prior to initiation of PD related therapy. This survey is to capture the subjects status at the time of the assessments. "A feedback survey will be used to assess study experience at each follow up time (6 and 12 month) 24 month Exercise Habit Feedback Survey -"this survey is to query the participants' exercise habits 1 year after completion of the study."
Adherence Assessments
Adherence will be documented in terms of the following: (1) number of sessions exercised per week; (2) length of exercise sessions; (3) average HR during exercise sessions; (4) percent time and minutes within target HR zone.
MANAGEMENT OF ADVERSE EXPERIENCES
Muscle soreness and strains are common with exercise and it is anticipated that some subjects will experience these events during the course of the study. Management and modification of the exercises will be managed on a case-by-case basis. Approved: 08/ 28/ 2014
It is possible that falls will occur. Should a fall occur during treadmill testing or exercise, the fall will be reported as a SAE or AE (depending on the outcomes of the fall). Specific causes will be determined and appropriate strategies will be instituted to minimize fall risk. For example, if the subject has exhibited unsafe behavior that can be changed (e.g., turning head to talk to person on the adjacent treadmill), safety procedures will be emphasized. If necessary, a harness will be used for safety with future exercise. Should an individual experience an adverse health event during exercise testing or training, emergency response procedures (for on-site events) will be followed by staff members certified in CPR and trained to respond to urgent and emergent situations. The subject will be required to undergo follow-up evaluation by the primary care provider, or appropriate specialist, and cleared for continuation in the study.
Reporting: AEs and SAEs will be documented by the research assistant, to whom they are divulged, as indicated below and their relatedness to the study will be indicated as appropriate in the electronic data base. Determination of relatedness will be made by site PI and will be confirmed by the SMC. AEs will be documented in the electronic data base for AEs within two days. SAEs will be reported within 24 hours as follows: Site PI notifies site IRB Note that the study personnel may not know of SAEs that are not study related until the monthly follow-up. If such events occur, they will be documented as above as soon as the study personnel are aware of their occurrence.
CRITERIA FOR INTERVENTION DISCONTINUATION
A subject would be discontinued from the study intervention if a medical condition develops that precludes the continuation of exercise. In such events as much follow-up data will be obtained as possible.
STATISTICAL CONSIDERATIONS
General Design Issues
The Primary Aim (PA1), on which this exploratory Phase II clinical trial is powered, and the primary Hypothesis (H1) is:
PA1: To test whether individuals with de novo Parkinson's disease (naïve to dopaminergic treatment) can achieve the randomly assigned levels of mean exercise intensity (60-65% average HRmax or 80-85% average HRmax) and adhere to the exercise protocol. H1: Patients assigned to the 80-85% HRmax group will exercise at a 20% higher relative intensity than those in the 60-65% HRmax group and both groups will demonstrate adherence levels of at least 3 days per week. The primary outcome for exercise intensity is derived from the average heart rate during the exercise sessions from weeks 9 to 26. The primary outcome for adherence is determined by the average number of days per week exercised and duration in minutes of exercise at the target HR.
The heart rate and adherence (date of visit) data will be uploaded directly from heart rate monitors.
The Secondary Aims (SA) are:
SA 2: To determine if intense endurance exercise warrants further investigation as a therapeutic intervention for motor symptoms in the treatment of de novo Parkinson's disease by conducting a futility trial. In an efficacy trial, the null hypothesis is that treatments are equivalent and rejection of the null hypothesis indicates one treatment is more effective than the other. In contrast, in a futility trial the null hypothesis is that the treatment has promise and will produce results exceeding a meaningful threshold. The alternate hypothesis in a futility trial is that treatment is not sufficiently different from control to warrant further investigation and is therefore futile.
H2:
The exercise groups will demonstrate potential for therapeutic efficacy using a futility threshold of =3.5 points ( = UPDRS control -UPDRS exercise ) on the UPDRS motor scale at 6 months or last visit prior to dopaminergic therapy being initiated, when compared with waitlisted no exercise control group. The primary outcome of the secondary aim is the change in the Unified Parkinson's Disease Rating Scale (Motor Score) from baseline to either 6 months or last off medication study visit (if initiating dopaminergic therapy prior to 6 months). The UPDRS Motor Score measures the severity of the symptoms of disease most appropriate for our study and is the gold standard in other PD trials. SA 3: To estimate the incidence of adverse events and 6-month attrition associated with endurance exercise for each exercise arm (i.e., mean 60-65% HRmax and mean 80-85% HRmax groups). H3: For each treatment arm, there will be a low incidence of exercise-related adverse events (10%) and 6-month attrition (<15%).
The primary outcomes of the third aim are adverse events defined as exercise-related discomforts, minor injuries, and , and falls and attrition defined as the number of subjects who discontinued exercise with no 6 month efficacy data or are otherwise to lost to follow-up. These outcomes are very relevant in determining the feasibility of a larger Phase III trial for exercise in PD. Adverse events and attrition will be monitored by the Steering Committee on a biweekly basis masked to the subjects exercise intervention assignment. At the initiation of the study an independent reviewer will monitor the heart rate and adherence data and will compare these data across the three sites to assure that there are no site specific discrepancies in adherence to the protocol. This trial is a randomized controlled Phase II futility trial to test the feasibility, potential efficacy, and safety of intense exercise in Parkinson's disease patients. Subjects will be randomized to three parallel groups: (1) usual care (2) exercise 4xper week at 60-65% HRmax (3) exercise 4x per week at 80-85% HRmax.
Justification for concurrent control group:
The Phase II futility design will guide our decisions about future larger trials involving intensive exercise in Parkinson's disease. Futility designs derived from cancer research have recently been used in the study of therapeutic interventions in PD 34, 35 but mainly in drug trials. 36, 37 Even in well defined drug trials, there is debate on whether to rely on historical placebo control treatment from such trials as DATATOP 38 versus using concurrent controls in conjuction with historical data (calibration controls). The placebo effect in PD drug therapy trials is widely recognized and does not reflect natural disease progression in de novo patients. Placebo controls from drug trials are not appropriate controls for exercise intervention studies because of the modality of the intervention; therefore, a concurrent wait-list control group is necessary for us to conduct the futility component of our study. 39 The same approach has recently been used in testing coenzyme Q10 in ALS 40 and brain oxygen monitoring for the treatment of brain injury. 41 Subjects assigned to the no-exercise arm will be randomized to an exercise arm after completing the 6-month control period. This approach will be taken because: 1) it is expected to enhance compliance in the control arm; 2) it addresses the ethical concern of asking subjects to join an exercise study and then asking them not to exercise; and 3) the exercise data can be included in a secondary analysis of attrittion.
Justification for 3.5 as futility threshold:
The futility threshold for this trial is based on: (1) previous futility trial designs, 34 (2) 6-month changes of motor scores in drug trials, 42, 43 and (3) minimal clinically important changes. 34 First, futility trials in PD have primarily been single-armed studies Approved: 08/ 28/ 2014 powered around =30% lessening of decline based on the UPDRS Total score at 12 months 34 compared to historical controls. The Elm study stated: "the choice of , the maximum allowable worsening, was relatively arbitrary", 34 and that other rates could be used if well justified. We are not using a percentage lessening of decline in motor symptoms at 6 months. Studies show minimal change in motor symptoms at 6 months ranging from 0 (no worsening) to 3.5.
38
Power analyses based on percentage lessening decline would result in unattainable sample sizes for null hypotheses that are not clinically meaningful. 34 Second, studies of ropinirole versus bromocriptine and ropinirole versus levodopa in de novo patients 43 showed 30%-35% improvement in motor scores at 6 months relative to baseline in the ropinirole arms, translating to 7 points absolute change. As we demonstrate in our third point, it is reasonable to postulate a 6-point change with exercise. Third, the minimal clinically important change (MCIC) in the UPDRS motor score at six months is a 5 unit improvement (-5) . 44 This MCIC applies to within-patient change, not difference in change between two intervention arms. We used an absolute difference of =3.5 in the 6-month UPDRS change between control and intervention as the lower boundary for what would be considered clinically important and worth further investigation. Our null hypothesis is that exercise improves change in motor scores by at least 3.5 points more than controls and the alternative is that exercise yields less than this improvement compared to controls. We used this conservative threshold, which is supported by preliminary data, to ensure that the sample size will be adequate. We anticipate that we will actually observe a 5-point difference in change in UPDRS between exercise and control arms because: 1) the intervention is 2 months longer than in our previous work (Schenkman, unpublished data), (2) we expect the high-intensity (80-85% HRmax) to enhance efficacy, and (3) we have evidence that improvement in UPDRS score measured on medication (Schenkman, unpublished data) is less than when measured off medication.
Randomization: Subjects will be randomized to three groups (1) usual care (2) exercise 4xper week at 60-65% HRmax (3) exercise 4x per week at 80-85% HRmax. Dr. Moore (biostatistician) will generate the randomization list in SAS version 9.2 using permuted block randomization stratified by site. The University of Pittsburgh Center for Research on Health Care Data Center systems analyst will load the randomization list into the web-based data management system such that allocation concealment will be preserved for consecutively enrolled patients. Subjects will be followed for 52 weeks after randomization. Six months (26 weeks) is the primary and secondary end point for two reasons: First, it is likely that most subjects will remain off of dopaminergic therapies for six months than 12 months. Second, we have greater assurance of compliance of the protocol as prescribed for six as compared to 12 months. Additional feasibility outcomes are at 12 months (52 weeks); this is important for two reasons. First, we will use the time to initiation of dopaminergic therapy to compare interventions for sample size estimates for the Phase III trial. Second, because PD is progressive, it is necessary for subjects to remain on exercise to generate lasting benefits. Therefore it will be important to establish feasibility of subjects remaining on the exercise regimen for 12 months.
Outcomes
Primary Outcome
The primary outcome measure for achieving levels of exercise intensity is derived from the average heart rate during an exercise session (HRex) and expressed as a percentage of the maximal heart rate for the individual: %HRmax=(HRex/HRmax) * 100. Because exercise intensity will be gradually increased over weeks 1 to 8 to the target intensity, we will use the daily session data from weeks 9 to 26 to calculate an average %HRex for each week and for the entire period. For adherence, we will determine the average number of days/wk exercised and duration (min.) of the exercise at the target HR.
Secondary Outcomes
(Aim 2) The change in the Unified Parkinson's Disease Rating Scale (Motor Score) from baseline to either 6 months or last off-medication study visit 45 will be the measure used for the futility component of the analysis. The UPDRS Motor score measures the severity of the symptoms of the disease, and is most appropriate for our study given that the overarching goal is to modify the Approved: 08/ 28/ 2014 symptoms of the disease. The change in the UPDRS Motor has been recognized as an outcome for futility studies along with onset of need for L-DOPA. It is important to emphasize that the non-futility threshold (i.e., beneficial changes in UPDRS) can still be met, even if subjects do not attain the prescribed intensity of exercise (i.e., do not reach the prescribed average HR Max and/or days of exercise). The UPDRS will be assessed at baseline, 3, 6, and 12 months. Some participants will initiate dopaminergic therapy during the course of the study. At 6 and 12 months, participants in "off" medication state for dopaminergic therapies will show improvement over their true trajectory if no therapy had been initiated. The amount of improvement is positively correlated with the duration of treatment. This could significantly impact the intervention effect estimates if one group has a higher rate of drug initiation. For the primary outcome of 6 month change, the UPDRS from the last off-medication study visit will be used for participants who initiate dopaminergic therapy prior to 6 months.
NOTE -should a participant require PD related medication before the 3-mo or 6-mo time points, an additional visit will be scheduled prior to initiation of the drug therapy during which the UPDRS and MDS-UPDRS will be administered. (Aim 3) Adverse Events (AEs) are defined as exercise-related discomforts (e.g., muscle and joint soreness/pain), minor injuries (e.g., strains, sprains), and non-injurious falls; and attrition is defined as the number of patients dropping out of the study. Serious Adverse Events (SAEs) are defined as hospitalization, surgery, death, or permanent disabilty. We will compare AEs, SAEs, and attrition by both treatment intervention and site.
Sample Size and Accrual
Sample size justification for Aim 1: Aim 1 will determine if subjects can achieve the target intensity of endurance exercise. The primary outcome is the average %HR max during exercise in weeks 9-26. The sample size analysis was based on within-group precision and comparisons to the targeted exercise intensity. Preliminary data were taken from a study of the effects of gender, age, and fitness level on response to training in 60-71 year olds. 6 The within-group standard deviations (SD) of %HRmax ranged from 5 to 6 at 6 months of training for men and women. We determined the number of subjects needed per exercise arm to provide good precision (±2.5%) for the average %HRmax. A sample size of 36 per arm produces a 95% confidence interval with half width of 2.4% (conservative =7.0, 80% upper bound for the SD) and 83% power to detect a difference of 3.5% from the specified intensity in each group ( =7, effect size=0.5, =0.05, twosided test). For Aim 1, we also want to establish that subjects assigned to 80-85% HRmax actually exercise at the expected higher intensity than the subjects assigned to 60-65% HRmax. Very few subjects would be needed to establish a 20% point difference between two groups given the standard deviations (effect size>2.0). We decided a priori that we want to be able to detect differences in relative exercise intensity as small as 5% between the two groups. With n=36 subjects per group and =7, we will have 85% power to detect a difference of 5% or greater between the two groups. A sample size of n=42 is required per exercise group if we assume an attrition rate of 15% at 6 months. With respect to adherence (average days exercised), with n=36 per group we will be able to estimate the average days exercised per week with 0.24 precision (95% CI, standard deviation=0.7) 6 . Sample size justification for Aim 2: For Aim 2, published and preliminary data for the UPDRS motor score in placebo groups show average decline ranging from 0.88 36 to ~3.47 38 points at 6 months and standard deviations of change ranging from 4.43 34 to 6.37 (Schenkman, unpublished data) to 6.68. 34 Another study suggested the natural progression of motor impairment measured by the UPDRS to be a 2-3 unit decline per year. 46 Concurrent placebo controls in a recent de novo PD study for creatine and minocycline 37 did not show as much decline as DATATOP controls for UPDRS Total scores. 38 Given these studies and the preliminary data from Schenkman (unpublished data) we assumed a 6 month change = 1 on the UPDRS motor for our usual care controls. We used a range of standard deviations from 5.5 to 6.5 and a one-sided =0.1 for the power analyses. The null hypothesis (non-futility) is that the difference in the rates of change is greater than =3.5 points (6 month change control group = 1, worsening; 6 month change exercise group = -2.5, improvement; = UPDRS control -UPDRS exercise ). The alternative Approved: 08/ 28/ 2014 hypothesis (futility) is that the difference in the rates is less than =3.5. An n=36 per group completing the study provides over 84% power to reject the null hypothesis of further testing if there is truly no difference in the rates of change in the UPDRS motor score between the control and exercise group.
Data Monitoring
The Study Monitoring Committee will review data for safety and adherence and will compare these data across sites. There are no planned interim analyses for efficacy or futility.
Data Analyses
Statistical Analyses Aim 1: Ave %HRmax: The analyses for Aim 1 are two-fold: (1) within-exercise group comparisons to test for differences from the specified exercise intensity of either 60-65% HRmax or 80-85% HRmax and (2) between-group comparisons to test for differences in achieved levels. We will estimate the overall average %HRmax and its corresponding 95% confidence interval for each exercise group at 6 months. We will then compare the average to the intended target intensity (62.5% or 82.5%) using a one-sample t-test ( =0.05). In addition, it will be important to look at changes in the average %HR max over time to determine if there was a pattern of increase or decrease. We will use a repeated measures analysis of weekly %HRmax stratified by group and employ linear mixed models to tests for any trends over time from weeks 9 to 26. For the second part of the analysis, we wish to test if the groups actually exercised at different levels of intensity even if they did not reach the intensity specified. We will use a two-sample t-test to compare the overall average %HRmax between the two groups over weeks 9 to 26 and combine the repeated measures analyses from both arms to test for any differential changes in performance over time.
The primary variables of interest in the repeated measures analysis would be the exercise group, time in weeks, and group*time.
Aim 1 Adherence:
All adherence analysis for Aim 1 will be specific to the treadmill exercise specified in the protocol. Descriptive statistics by exercise group will be calculated for average number of days per week exercised (primary adherence measure) and duration of time (mins) they exercise at the specified intensity. We will determine if the 95% confidence interval for average number of exercise days per week falls above 3 days to test the hypothesis that subjects in each exercise group demonstrate adherence levels of more than 3 days per week.
Aim 2: Futility threshold of =3.5 points: In futility trials, the null hypothesis is that the intervention should be studied further (non-futility) and the alternative hypothesis is that no more investigation is warranted (futility). We are using this strategy to guide our decisions about larger trials involving intensive exercise in PD. The outcome is defined as the 6-month change in the UPDRS Motor Scores (6 months measurement -baseline). An increase in the UPDRS motor scores infers worsening of symptoms and a decrease infers improvement of symptoms. We will use the intention to treat 'as randomized' treatment assignment for each subject regardless of adherence. For the primary outcome of 6 month change, the UPDRS from the last off-medication study visit will be used for participants who initiate dopaminergic therapy prior to 6 months. We will compare the rate of change in each exercise group to the concurrent controls: control group rate of change -exercise group rate of change, such that a positive difference implies the exercise group is doing better than the control group. We will use a two-sample t-test with onesided =0.10 for the efficacy analysis and a futility threshold of =3.5 points on the UPDRS motor scale. We will also calculate the null-adjusted (-3.5) difference in the rates and a 90% confidence interval (upper bound for the null-adjusted difference in the rates). In secondary analyses, we will adjust for any baseline variable that either statistically or clinically differs between groups. Aim 3: Adverse events and levels of attrition: The analyses for Aim 3 are two-fold: betweenexercise group comparisons and across-site comparisons. The 6-month incidence of individual AEs (including SAEs) and exact confidence intervals will be calculated for each group. We will use Fisher's exact or Poisson exact tests to compare exercise groups for AEs that are definitely, Approved: 08/ 28/ 2014
probably, or possibly related to the exercise interventions. We define attrition as incomplete 6-month data for primary disease outcomes and incomplete monthly data for secondary outcomes.
We will estimate the 6-month attrition using proportions and 95% confidence intervals. We will also monitor the percent of targeted recruitment numbers, and protocol deviations. In secondary analysis, we will combine attrition data from the original exercise groups with data from the control group after exercise participation (see section C.5.1 and Figure 2 ). Additional Analyses: We will conduct three sets of analyses that expand and illuminate the specific analyses proposed in the specific aims. The first set of analyses is designed to gain greater insight into whether additional variables may account for our findings in Aims 1 and 2 and may inform a Phase III clinical trial. Three such analyses are proposed based on: 1) the average physical activity level measured by via physical activity monitors, 2) the initial cardiovascular fitness of the subjects as determined by VO2 max from the stress test, and 3) PD subgroup. The second set of analyses is designed to determine if dose of exercise affects quality of life as a secondary outcome. In the third set of analyses, we will explore the impact if participants initiating dopaminergic treatment on intervention affects using "off" medication state at 6 months and using "just prior to treatment initiation" UPDRS assessments. These analyses are informative for not only planning the larger confirmatory study but they will contribute methodological information for future studies in de novo patients. Physical activity data are measured monthly for 6 months on all subjects and will be treated as continuous data in total number of activity counts. We are particularly interested in the impact high intensity exercise has on other physical activity. We will use linear mixed models to compare all three groups with respect to physical activity outside of the pre-specified protocol treadmill walking. Models will include fixed effects for group, time, and group*time and random effect for subject and time (if pattern is linear) to account for repeated measures. We will use AN-COVA to adjust for initial baseline fitness as measured by VO2 max and to explore potential attenuating effects of high baseline fitness on exercise for PD symptoms. We will use regression analysis to explore if PD subgroup modifies the response of patients to exercise. We will use ANCOVA to compare the PDQ at six months among the three intervention groups controlling for baseline PDQ.
Other statistical considerations (missing data, initiation of drug therapy): We do not expect substantial item response missing data due to the electronic nature of data collection that is used by the Center for Research on Health Care Data Center (CRHC-DC). We anticipate <15% attrition at the 6-month assessment based on our pilot work and have accounted for this in sample size analyses. We will compare baseline characteristics between subjects with the 6-month assessment to those without to assess potential biases. We will try to obtain reasons for study drop out so that we can assess the missing data mechanism. We will use linear mixed models for analysis of weekly %HRmax that are more robust to missing data than traditional multivariate models. Lost to follow-up: for subjects missing 6-month follow-up data on the primary futility measure (UPDRS), we will conduct several sensitivity analyses. First, we will assign the worst change score observed within each intervention arm to evaluate the impact on our study results. 36, 37 Secondly, we will also use a "nearest neighbor" approach where best-and worst case scenarios are created by imputing values of the best and worst decline in the UPDRS motor scores from 5 subjects that had similar baseline UPDRS scores. 47 Third, we will use multiple imputation in exploratory analyses. These three approaches should result in consistent results if our findings are robust to missing data. We will declare futility if at least two of these analyses with different missing data methods show futility. If only one of these analyses shows futility, we will thoroughly assess the assumptions for the missing data approach and determine if the assumptions are reasonable based on the data available for missing visits and baseline variables associated with attrition. In all scenarios, the final futility or non-futility decision will be discussed with the Study Monitoring Committee and final decision will be made with the SMC's approval. Approved: 08/ 28/ 2014 ment to assure that targets are met. The Chair will write a report after each meeting, summarizing the study status and outlining any concerns. A copy of this report will be given to Barb Hammack, Research Subject Advocate.
HUMAN SUBJECTS
Institutional Review Board (IRB) Review and Informed Consent
This protocol and the informed consent document and any subsequent modifications will be reviewed and approved by the IRB or ethics committee responsible for oversight of the study at each site. A signed consent form will be obtained from the subject. The consent form will describe the purpose of the study, the procedures to be followed, and the risks and benefits of participation. A copy of the consent form will be given to the subject and this fact will be documented in the subject's record.
Subject Confidentiality
All laboratory specimens, evaluation forms, reports, and other records that leave the site will be identified only by the Study Identification Number (SID) to maintain subject confidentiality. All records will be kept in a locked file cabinet. All computer entry and networking programs will be done using SIDs only. Clinical information will not be released without written permission of the subject, except as necessary for monitoring by IRB, the FDA, the NINDS, the OHRP, or the sponsor's designee.
Study Modification/Discontinuation
The study may be modified or discontinued at any time by the IRB, the NINDS, the OHRP, the FDA, or other government agencies as part of their duties to ensure that research subjects are protected.
PUBLICATION OF RESEARCH FINDINGS
Publication of the results of this trial will be governed by the policies and procedures developed by the Executive Committee. Any presentation, abstract, or manuscript will be made available for review by the NINDS prior to submission.
